62 related articles for article (PubMed ID: 17083342)
21. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
22. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
[TBL] [Abstract][Full Text] [Related]
23. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
24. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
[TBL] [Abstract][Full Text] [Related]
26. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
27. Management of symptomatic, untreated chronic lymphocytic leukemia.
Kasamon YL; Flinn IW
Blood Rev; 2007 May; 21(3):143-56. PubMed ID: 17097783
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic strategies to meet infectious complications in fludarabine-treated CLL.
Südhoff T; Arning M; Schneider W
Leukemia; 1997 Apr; 11 Suppl 2():S38-41. PubMed ID: 9178837
[TBL] [Abstract][Full Text] [Related]
29. Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia.
Kay NE
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S50-4. PubMed ID: 16549115
[TBL] [Abstract][Full Text] [Related]
30. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
Leporrier M
Hematol J; 2004; 5 Suppl 1():S10-9. PubMed ID: 15079149
[TBL] [Abstract][Full Text] [Related]
31. Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia.
Lamanna N; Weiss MA
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S44-9. PubMed ID: 16549114
[TBL] [Abstract][Full Text] [Related]
32. The clinical and epidemiological burden of chronic lymphocytic leukaemia.
Redaelli A; Laskin BL; Stephens JM; Botteman MF; Pashos CL
Eur J Cancer Care (Engl); 2004 Jul; 13(3):279-87. PubMed ID: 15196232
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with fludarabine in leukaemia.
Keating MJ; Estey E; O'Brien S; Kantarjian H; Robertson LE; Plunkett W
Drugs; 1994; 47 Suppl 6():39-49. PubMed ID: 7525188
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
Kowal M; Dmoszyńska A; Lewandowski K; Hellmann A; Wegrzyn J; Skotnicki AB; Wołowiec D; Kuliczkowski K; Piszcz J; Kłoczko J; Roznowski K; Komarnicki M
Leuk Lymphoma; 2004 Jun; 45(6):1159-65. PubMed ID: 15359995
[TBL] [Abstract][Full Text] [Related]
35. [A new purine analog in the treatment of hematologic malignancy. I. Fludarabine].
Vásová I; Penka M; Hájek R; Mayer J; Krahulcová E
Vnitr Lek; 1997 Jan; 43(1):45-50. PubMed ID: 9221567
[TBL] [Abstract][Full Text] [Related]
36. Pentostatin in chronic lymphocytic leukemia.
Sauter C; Lamanna N; Weiss MA
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1217-22. PubMed ID: 18721115
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia.
Hallek M; Eichhorst BF
Hematol J; 2004; 5 Suppl 1():S20-30. PubMed ID: 15079150
[TBL] [Abstract][Full Text] [Related]
38. The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Lenz G; Hiddemann W; Dreyling M
Cancer; 2004 Sep; 101(5):883-93. PubMed ID: 15329894
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
Richards S
Cancer Treat Rev; 2005 Jun; 31(4):332-5. PubMed ID: 15894429
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
